



# SAFETY DATA SHEET

Revision date 06-Dec-2021

Version 1.02

Page 1 / 12

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

<b>Product Name</b>	Epinephrine Injection (Hospira, Inc.)
<b>Product Code(s)</b>	PZ03223
<b>Trade Name:</b>	Not applicable
<b>Chemical Family:</b>	Not determined

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

<b>Recommended Use</b>	Pharmaceutical product used for allergic reactions (anaphylaxis)
------------------------	--

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
 275 North Field Drive  
 Lake Forest, Illinois 60045  
 1-800-879-3477

Hospira UK Limited  
 Horizon  
 Honey Lane  
 Hurley  
 Maidenhead, SL6 6RJ  
 United Kingdom

### 1.4. Emergency telephone number

<b>Emergency Telephone</b>	CHEMTREC (24 hours): 1-800-424-9300
<b>E-mail address</b>	pfizer-MSDS@pfizer.com

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

Not classified as hazardous

### 2.2. Label elements

<b>Signal word</b>	Not Classified
--------------------	----------------

<b>Hazard statements</b>	Not classified in accordance with international standards for workplace safety.
--------------------------	---

### 2.3. Other hazards

<b>Other hazards</b>	An Occupational Exposure Value has been established for one or more of the ingredients (see Section 8).
----------------------	---

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 2 / 12  
Version 1.02

**Note:** This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

**3.1 Substances**  
**Substances** Not applicable

**3.2 Mixtures**

Hazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Sodium bisulfite 7631-90-5	<2.0		231-548-0	Acute Tox. 4 (H302) (EUH031)	Not Listed	No data available	No data available
SODIUM CHLORIDE 7647-14-5	*		231-598-3	No data available	Not Listed	No data available	No data available
Epinephrine 51-43-4	1.0		200-098-7	Acute Tox. 2 (H300) Acute Tox. 2 (H310)	Not Listed	No data available	No data available
+ Hydrochloric Acid 7647-01-0	**		231-595-7	Acute Tox. 3 (H331) Skin Corr. 1A (H314) Press. Gas	Eye Irrit. 2 :: 10%<=C<25% Skin Corr. 1B :: C>=25% Skin Irrit. 2 :: 10%<=C<25% STOT SE 3 :: C>=10%	No data available	No data available

NonHazardous

Chemical name	Weight-%	REACH Registration Number	EC No	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Water 7732-18-5	*		231-791-2	No data available	Not Listed	No data available	No data available
Sodium citrate 68-04-2	*		200-675-3	No data available	Not Listed	No data available	No data available

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate  
No information available

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 3 / 12  
Version 1.02

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Water 7732-18-5	89838.9	No data available	No data available	No data available	No data available
Sodium bisulfite 7631-90-5	1310	No data available	No data available	No data available	No data available
SODIUM CHLORIDE 7647-14-5	3000	10000	No data available	No data available	No data available
Epinephrine 51-43-4	No data available	62	No data available	No data available	No data available
+ Hydrochloric Acid 7647-01-0	238	5010	No data available	No data available	563.3022

## Additional information

\* Proprietary

\*\* to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>Inhalation</b>	Remove to fresh air. Seek immediate medical attention/advice.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

**Most important symptoms and effects** For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

### 4.3. Indication of any immediate medical attention and special treatment needed

**Note to physicians** None.

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

**Suitable Extinguishing Media** Dry chemical, CO2, alcohol-resistant foam or water spray.

### 5.2. Special hazards arising from the substance or mixture

**Specific hazards arising from the chemical** Fine particles (such as mists) may fuel fires/explosions.

**Hazardous combustion products** Formation of toxic gases is possible during heating or fire.

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 4 / 12  
Version 1.02

## 5.3. Advice for firefighters

**Special protective equipment for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## **Section 6: ACCIDENTAL RELEASE MEASURES**

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.

**Methods for cleaning up** Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## **Section 7: HANDLING AND STORAGE**

### 7.1. Precautions for safe handling

#### **Advice on safe handling**

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

### 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical drug product.

## **Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION**

### 8.1. Control parameters

#### **Exposure Limits**

Refer to available public information for specific member state Occupational Exposure Limits.

#### **Sodium bisulfite**

ACGIH TLV 5 mg/m<sup>3</sup>

Denmark 5 mg/m<sup>3</sup>

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 5 / 12  
Version 1.02

---

France	5 mg/m <sup>3</sup>
Ireland	5 mg/m <sup>3</sup>
	STEL: 15 mg/m <sup>3</sup>
Russia	MAC: 5 mg/m <sup>3</sup>
Spain	5 mg/m <sup>3</sup>
Switzerland	5 mg/m <sup>3</sup>
OSHA PEL	(vacated) TWA: 5 mg/m <sup>3</sup>
United Kingdom	TWA: 5 mg/m <sup>3</sup>
	STEL: 15 mg/m <sup>3</sup>
<b>SODIUM CHLORIDE</b>	
Latvia	5 mg/m <sup>3</sup>
Russia	MAC: 5 mg/m <sup>3</sup>
<b>+ Hydrochloric Acid</b>	
ACGIH OEL (Ceiling)	2 ppm
ACGIH TLV	Ceiling: 2 ppm
Austria	5 ppm
	8 mg/m <sup>3</sup>
	STEL 10 ppm
	STEL 15 mg/m <sup>3</sup>
Bulgaria	STEL: 10 ppm
	STEL: 15.0 mg/m <sup>3</sup>
	5 ppm
	8.0 mg/m <sup>3</sup>
Czech Republic	8 mg/m <sup>3</sup>
	Ceiling: 15 mg/m <sup>3</sup>
Denmark	Ceiling: 5 ppm
	Ceiling: 8 mg/m <sup>3</sup>
Estonia	5 ppm
	8 mg/m <sup>3</sup>
	STEL: 10 ppm
	STEL: 15 mg/m <sup>3</sup>
European Union	TWA: 5 ppm
	TWA: 8 mg/m <sup>3</sup>
	STEL: 10 ppm
	STEL: 15 mg/m <sup>3</sup>
Finland	STEL: 5 ppm
	STEL: 7.6 mg/m <sup>3</sup>
Germany	2 ppm
	3.0 mg/m <sup>3</sup>
	Ceiling / Peak: 4 ppm
	Ceiling / Peak: 6 mg/m <sup>3</sup>
Germany	2 ppm
	3 mg/m <sup>3</sup>
Hungary	8 mg/m <sup>3</sup>
	STEL: 16 mg/m <sup>3</sup>
Ireland	8 mg/m <sup>3</sup>
	5 ppm
	STEL: 10 ppm
	STEL: 15 mg/m <sup>3</sup>
Italy	5 ppm
	8 mg/m <sup>3</sup>
	STEL: 10 ppm
	STEL: 15 mg/m <sup>3</sup>
Ceiling Limit Value	2 ppm
	3.0 mg/m <sup>3</sup>
Latvia	5 ppm
	8 mg/m <sup>3</sup>
	STEL: 10 ppm
	STEL: 15 mg/m <sup>3</sup>
Netherlands	8 mg/m <sup>3</sup>

---

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 6 / 12  
Version 1.02

Poland	STEL: 15 mg/m <sup>3</sup> STEL: 10 mg/m <sup>3</sup> 5 mg/m <sup>3</sup>
Romania	5 ppm 8 mg/m <sup>3</sup> STEL: 10 ppm
Russia	STEL: 15 mg/m <sup>3</sup> MAC: 5 mg/m <sup>3</sup>
Slovakia	5 ppm 8.0 mg/m <sup>3</sup>
Spain	5 ppm 7.6 mg/m <sup>3</sup> STEL: 10 ppm STEL: 15 mg/m <sup>3</sup>
Switzerland	2 ppm 3 mg/m <sup>3</sup> STEL: 4 ppm STEL: 6 mg/m <sup>3</sup>
U.S. - OSHA - Final PELs - Ceiling Limits	5 ppm 7 mg/m <sup>3</sup>
OSHA PEL	(vacated) Ceiling: 5 ppm (vacated) Ceiling: 7 mg/m <sup>3</sup> Ceiling: 5 ppm Ceiling: 7 mg/m <sup>3</sup>
United Kingdom	TWA: 1 ppm TWA: 2 mg/m <sup>3</sup> STEL: 5 ppm STEL: 8 mg/m <sup>3</sup>

## SODIUM CHLORIDE

Pfizer Occupational Exposure Band (OEB): OEB 1 (control exposure to the range of 1000ug/m<sup>3</sup> to 3000ug/m<sup>3</sup>)

## Epinephrine

Pfizer Occupational Exposure Band (OEB): OEB 4 - Skin (control exposure to the range of 1ug/m<sup>3</sup> to <10ug/m<sup>3</sup>, provide additional precautions to protect from skin contact)

## 8.2. Exposure controls

### Engineering controls

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

### Environmental exposure controls

No information available.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious disposable gloves (e.g. Nitrile, etc.) (double recommended) if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Wear impervious protective clothing to prevent skin contact – consider use of disposable clothing where appropriate. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 7 / 12  
Version 1.02

**Respiratory protection** Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a full mask, P3 filter). (Respirators must meet the standards in accordance with EN136, EN143, ASTM F2704-10 or international equivalent.).

**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

Physical state	Liquid
Color	Clear Colorless
Odor	No information available.
Odor threshold	No information available
Molecular formula	Mixture
Molecular weight	Mixture

#### Property

#### Values

pH	2.2-5.0
Melting point / freezing point	No data available
Boiling point / boiling range	
Flash point	No information available
Evaporation rate	No data available
Flammability (solid, gas)	No data available
Flammability Limit in Air	
Upper flammability limit:	No data available
Lower flammability limit:	No data available
Vapor pressure	No data available
Vapor density	No data available
Relative density	~1
Water solubility	No data available
Solubility(ies)	Soluble Water
Partition coefficient	No data available
Autoignition temperature	No data available
Decomposition temperature	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available
Explosive properties	No information available

### 9.2. Other information

No information available

#### 9.2.1. Information with regard to physical hazard classes

No information available

#### 9.2.2. Other safety characteristics

No information available

## Section 10: STABILITY AND REACTIVITY

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 8 / 12  
Version 1.02

## 10.1. Reactivity

**Reactivity** No data available.

## 10.2. Chemical stability

**Stability** Stable under normal conditions.

### **Explosion data**

**Sensitivity to Mechanical Impact** No data available.

**Sensitivity to Static Discharge** No data available.

## 10.3. Possibility of hazardous reactions

**Possibility of hazardous reactions** No information available.

## 10.4. Conditions to avoid

**Conditions to avoid** Fine particles (such as dust and mists) may fuel fires/explosions.

## 10.5. Incompatible materials

**Incompatible materials** As a precautionary measure, keep away from strong oxidizers.

## 10.6. Hazardous decomposition products

**Hazardous decomposition products** No data available.

## **Section 11: TOXICOLOGICAL INFORMATION**

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

**General Information:** The information included in this section describes the potential hazards of the individual ingredients

**Short term** May be absorbed through the skin and cause systemic effects. May be absorbed through mucous membranes and cause systemic effects.

**Known Clinical Effects:** Adverse effects associated with therapeutic use include increased heart rate (tachycardia), palpitations, sweating, nausea, vomiting, difficulty breathing, dizziness, weakness, headache, anxiety, nervousness.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### **SODIUM CHLORIDE**

Rat Sub-tenon injection (eye) LC50/1hr > 42 g/m<sup>3</sup>

Rat Oral LD 50 3 g/kg

Mouse Oral LD 50 4 g/kg

Rabbit Dermal LD 50 > 10 g/kg

#### **Epinephrine**

Rat Dermal LD50 62 mg/kg

Rat Oral LD50 30 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Water	> 90 mL/kg ( Rat )	-	-
Sodium bisulfite	= 1310 mg/kg ( Rat )	-	-
SODIUM CHLORIDE	= 3 g/kg ( Rat )	> 10000 mg/kg ( Rabbit )	> 42 mg/L ( Rat ) 1 h
Epinephrine		= 62 mg/kg ( Rat )	-
+ Hydrochloric Acid	238 - 277 mg/kg ( Rat )	> 5010 mg/kg ( Rabbit )	= 1.68 mg/L ( Rat ) 1 h

### Irritation / Sensitization: (Study Type, Species, Severity)

#### **SODIUM CHLORIDE**

Skin irritation Rabbit Mild

Eye irritation Rabbit Mild

#### **+ Hydrochloric Acid**

Skin irritation Severe

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 9 / 12  
Version 1.02

Eye irritation Severe

## **Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))**

### **Epinephrine**

Embryo / Fetal Development Rat Intravenous Dose not specified Not teratogenic  
Embryo / Fetal Development Rabbit Subcutaneous 30 times human dose LOAEL Developmental toxicity  
Embryo / Fetal Development Mouse Subcutaneous 7 times human dose LOAEL Developmental toxicity

## **Genetic Toxicity: (Study Type, Cell Type/Organism, Result)**

### **Epinephrine**

Bacterial Mutagenicity (Ames) *Salmonella* Negative  
Sister Chromatid Exchange Negative with activation  
Sister Chromatid Exchange Chinese Hamster Ovary (CHO) cells Equivocal without activation

### **+ Hydrochloric Acid**

Bacterial Mutagenicity (Ames) *Salmonella* Negative  
*In Vivo* Micronucleus Rat Negative

### **Carcinogenicity**

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. See below

### **Sodium bisulfite**

IARC

Group 3 (Not Classifiable)

### **+ Hydrochloric Acid**

IARC

Group 3 (Not Classifiable)

## **11.2. Information on other hazards**

### **11.2.1. Endocrine disrupting properties**

**Endocrine disrupting properties** No information available.

### **11.2.2. Other information**

**Other adverse effects** No information available.

## **Section 12: ECOLOGICAL INFORMATION**

### **Environmental Overview:**

Environmental properties have not been investigated. Releases to the environment should be avoided.

### **12.1. Toxicity**

**No information available**

### **12.2. Persistence and degradability**

**Persistence and degradability** No information available.

### **12.3. Bioaccumulative potential**

**Bioaccumulation** No information available.

### **12.4. Mobility in soil**

**Mobility in soil** No information available.

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 10 / 12  
Version 1.02

## 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment** No information available.

Chemical name	PBT and vPvB assessment
Sodium bisulfite	The substance is not PBT / vPvB PBT assessment does not apply
Sodium citrate	The substance is not PBT / vPvB PBT assessment does not apply
SODIUM CHLORIDE	The substance is not PBT / vPvB PBT assessment does not apply
+ Hydrochloric Acid	The substance is not PBT / vPvB PBT assessment does not apply

## 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** No information available.

## 12.7. Other adverse effects

No information available.

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

#### Other Information

The US Federal EPA waste listing for epinephrine does not include epinephrine salts. Disposal should be performed in accordance with all federal, state, and local regulatory requirements.

Chemical name	RCRA - F Series Wastes	RCRA - K Series Wastes	RCRA - P Series Wastes	RCRA - U Series Wastes
Epinephrine	-	-	Present	-

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Water

CERCLA/SARA Section 313 de minimus %

Not Listed

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
 Revision date 06-Dec-2021

Page 11 / 12  
 Version 1.02

<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-791-2
<b>AICS</b>	Present
Sodium bisulfite	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>Hazardous Substances RQs</b>	5000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-548-0
<b>AICS</b>	Present
Sodium citrate	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	200-675-3
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5
SODIUM CHLORIDE	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-598-3
<b>AICS</b>	Present
Epinephrine	
<b>CERCLA/SARA Section 313 de minimus %</b>	Not Listed
<b>Hazardous Substances RQs</b>	1000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	200-098-7
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 3 Schedule 4
+ Hydrochloric Acid	
<b>CERCLA/SARA Section 313 de minimus %</b>	1.0 %
<b>Hazardous Substances RQs</b>	5000 lb
<b>California Proposition 65</b>	Not Listed
<b>TSCA</b>	Present
<b>EINECS</b>	231-595-7
<b>AICS</b>	Present
<b>Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)</b>	Schedule 5 Schedule 6

Chemical name	French RG number	Title
Sodium bisulfite 7631-90-5	RG 66	-
SODIUM CHLORIDE 7647-14-5	RG 78	-

**European Union**

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

**Authorizations and/or restrictions on use:**

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

Chemical name	Restricted substance per REACH Annex XVII	Substance subject to authorization per REACH Annex XIV
Epinephrine - 51-43-4	Use restricted. See item 75.	

# SAFETY DATA SHEET

Product Name Epinephrine Injection (Hospira, Inc.)  
Revision date 06-Dec-2021

Page 12 / 12  
Version 1.02

+ Hydrochloric Acid - 7647-01-0	Use restricted. See item 75.	
---------------------------------	------------------------------	--

## Persistent Organic Pollutants

Not applicable

## Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

Chemical name	Lower-tier requirements (tons)	Upper-tier requirements (tons)
+ Hydrochloric Acid - 7647-01-0	25	250

Chemical name	Plant protection products directive (91/414/EEC)
SODIUM CHLORIDE - 7647-14-5	Plant protection agent

Chemical name	EU - Biocides
+ Hydrochloric Acid - 7647-01-0	Product-type 2: Disinfectants and algaecides not intended for direct application to humans or animals

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

## 15.2. Chemical safety assessment

**Chemical Safety Report** No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

#### Full text of H-Statements referred to under section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed Acute toxicity, oral-Cat.2; H300 - Fatal if swallowed Acute toxicity, dermal-Cat.2; H310 - Fatal in contact with skin Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

**Data Sources:** Safety data sheets for individual ingredients. Publicly available toxicity information.

**Reason for revision** Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

**Revision date** 06-Dec-2021

**Prepared By** Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**